Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by RalphRalphon Jul 23, 2019 5:22pm

161 Views

Post# 29952685

RE:RE:RE:RE:RE:A new prospectus

From today's prospectus, "Use of Proceeds" section:

"The reproductive toxicology studies for ATB-346 will be conducted in animals and are a key regulatory requirement for drug approval. The first tranche of these studies are expected to commence in calendar Q4 2019 and take approximately six months to complete. The regulatory consulting fees are for preparation for the Company’s Investigational New Drug (“IND”) filing with the FDA, and pre-IND and end-of-Phase 2 meetings with the FDA. The Company has retained a leading regulatory consulting agency based out of Washington, DC to support this preparatory work over the next six months. The health economics, payor and market opportunity studies will utilize industry standard methodology to formally characterize the commercial potential of ATB-346 based upon primary (physician and payor interviews) and secondary research. The studies are expected to take approximately 2-3 months to complete. The Company believes that the findings of these studies should be valuable in future partnering discussions."

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December